howard h pien executive profile  biography  bloomberg july    pm et biotechnology company overview of juno therapeutics inc snapshotpeople  overviewboard memberscommittees executive profile howard h pien chairman juno therapeutics incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr howard h pien serves as an advisor to the life sciences practice at warburg pincus mr pien serves as a partner of warburg pincus he served as the chief executive officer and president of medarex inc from june   to september  he joined medarex inc in june  he served as the chief executive officer and president of chiron corp from april  to  from april  to june  he performed consulting services from  to  he served  various executive positions at glaxosmithkline plc and smithkline beecham as president of us international and pharmaceuticals he joined chiron from glaxosmithkline gsk which resulted from the merger of glaxo wellcome and smithkline beecham limited where he served over twelve years in positions of international and global management responsibility including the positions as head of the international business mr pien served as the president of pharmaceuticals international at glaxosmithkline plc from december  to march  including service as a member of the corporate executive team president of pharmaceuticals smithkline beecham from  to  president of pharmaceuticalsnorth america smithkline beecham since  senior vice president and director of north asia since  managing director and senior vice president of united kingdom from  to  vice president and director of marketing of us from  to  vice president and director of product marketing of us heading the arthritis cardiovascular and vaccine groups from  to  and vice president and director of new product development of us from  to  prior to joining smithkline beecham he served six years at abbott laboratories and five years at merck  co in positions of sales marketing research licensing and product management he has over  years of pharmaceutical and biotechnology industry experience he served as an executive officer of smithkline beecham limited he has been the chairman of juno therapeutics inc since september  he has been chairman of sapience therapeutics inc since march   he serves as chairman of indivior plc and has been its director since november   he served as the non executive chairman of vanda pharmaceuticals inc from december  to march  he served as the chairman of chiron corp from  to  from  to september  he served as chairman of medarex inc he has been a member of corporate advisory board at x pharmaceuticals inc since april   he serves as a director of bellero phon he has been a director at juno therapeutics inc since january   immunogen inc since november   he served as an independent director of vanda pharmaceuticals inc from june  to june   he served as a director of viropharma inc from may  to january   and served as its lead independent director from december  to january   he served as an independent director of ikaria inc since april   he served as a director at sage therapeutics inc since april   until june   mr pien served as a director of rbp global holdings limited from march   to november   he served as a director of talon therapeutics inc since april   he served as a director of arresto biosciences inc he served as a director of medarex inc from june   to september  he served as a director of chiron corp since april  he served as a director of viropharma inc from august  to  he served as director of immunogen inc from january   to may   he serves as a director of several nonprofit organizations including childrens hospital  research center in oakland ca california healthcare institute the biotechnology industry association bio and the pharmaceutical research and manufacturers of america phrma he serves as director of the industry associations bio and phrma as well as oakland childrens hospital and fox chase hospital mr pien holds a bs degree in engineering from massachusetts institute of technology in  and an mba from the carnegiemellon university in read full background corporate headquarters  westlake avenue northseattle washington united statesphone fax  board members memberships presentindependent directorimmunogen incpresentdirectortalon therapeutics incpresentchairmanjuno therapeutics incpresentchairmanindivior plcpresentchairmansapience therapeutics inc education mba carnegie mellon universitybs massachusetts institute of technology other affiliations immunogen incviropharma incchiron corpglaxosmithkline plcsmithkline beecham limitedmedarex inccarnegie mellon universitymassachusetts institute of technologytalon therapeutics incikaria incvanda pharmaceuticals incsage therapeutics incindivior plcrbp global holdings limitedx pharmaceuticals incsapience therapeutics inc annual compensation there is no annual compensation data available stocks options exercisable optionsunexercisable optionstotal number of options total compensation total calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationrandal j kirk jdchairman and chief executive officerintrexon corporationcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact juno therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close howard h pien advisor x pharmaceuticals timesjavascript is disabled market profiles login sign up login sign up   edit person howard h pien location philadelphia pa add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop howard h pien location philadelphia pa add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop mr pien has been a chairman of vanda pharmaceuticals a cns development company and lead independent director of viropharma inc an orphan disease company additionally he currently sits on the board of directors of immunogen inc and juno therapeutics and is also an advisor to the life sciences practice of warburg pincus he is the former chief executive officer and chairman of medarex inc where he served for two years prior to the company’s acquisition by bristolmyers squibb company in  while at medarex mr pien shepherded the evolution of the company from a technology platform enterprise to a promising developer of oncology and immunology product candidates prior to medarex he served as president and chief executive officer of chiron corporation from  until its acquisition by novartis in  mr pien held an year tenure at glaxosmithkline and its predecessor smithkline beecham most recently serving as president of glaxosmithkline international earlier in his career mr pien held roles of increasing responsibility at abbott laboratories and at merck  co  companies in career na related markets  colleagues na related investments alias na industry pharmaceuticals tags na topics of influence web site na careers achievements investments related people edit view all howard h piencareer  apr x pharmaceuticals advisor  sage therapeutics board member jan juno therapeutics board member nov immunogen inc board member sage therapeutics board member competencies edit view all howard h pieneducation   carnegie mellon university finance marketing  massachusetts institute of technology civil engineering edit howard h pienachievements and recognitions add milestone no milestones has been recorded for howard h pien edit howard h pienlinks add link no links has been recorded for howard h pien howard h pieninvestmentsacquisitions no investments has been recorded for howard h pien howard h pieninvestments representing others no investment reps has been recorded for howard h pien howard h pienrelated people colleagues at x pharmaceuticals sudha parasuraman chief medical officer jan sudha parasuraman chief medical officer jan jessica christo vice president operations dec renato skerlj co founder jul view all howard h pienrecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees  companies about vanda  vanda pharmaceuticals   home  news  careers  contact us about vanda products pipeline partnering investor relations about vandaboard of directors howard h piendirector howard h pien has served a director of vanda since june  previously mr pien served as chairman of the board at vanda from december  until march  mr pien served as president and chief executive officer and a director of medarex inc from  until  when it was acquired by bristolmyers squibb prior to his tenure at medarex mr pien served as president and chief executive officer of chiron corporation until april  when it was acquired by novartis he joined chiron from glaxosmithkline formerly smithkline beecham where he served as president pharmaceuticals for smithkline beecham and later as president of glaxosmithklines international pharmaceuticals business mr pien has also held positions in sales market research licensing and product management at abbott laboratories and merck  co mr pien currently serves as a director of immunogen indivior plc as nonexecutive chairman juno therapeutics as nonexecutive chairman and sage therapeutics all of which are public companies engaged in drug development andor commercialization mr pien previously served on the boards of viropharma ikaria talon therapeutics chiron medarex and oakland childrens hospital mr pien earned a bs from the massachusetts institute of technology and an mba from carnegiemellon university « return to board of directors overview        management        board of directors          home  about vanda  products  pipeline  partnering  investor relations  news  careers  contact us copyright   vanda pharmaceuticals  terms  conditions  privacy policy sage therapeutics appoints howard h pien to the company’s board of directors  business wire sage therapeutics appoints howard h pien to the company’s board of directors pien brings expansive commercial expertise to sages rapidly advancing pipeline april    am eastern daylight time cambridge massbusiness wiresage therapeutics a biopharmaceutical company developing novel medicines to treat lifethreatening rare central nervous system cns disorders today announced the appointment of howard h pien to the company’s board of directors “howard is a seasoned industry leader with deep biopharmaceutical expertise especially in guiding companies as they expand and evolve from research and development to clinical stage” said jeff jonas md chief executive officer of sage therapeutics “we are pleased to welcome him to the sage team and believe he will be an invaluable asset as we advance our clinical and preclinical programs in orphan and acute cns disorders including status epilepticus” mr pien has been a chairman of vanda pharmaceuticals a cns development company and lead independent director of viropharma inc an orphan disease company additionally he currently sits on the board of directors of immunogen inc and juno therapeutics and is also an advisor to the life sciences practice of warburg pincus he is the former chief executive officer and chairman of medarex inc where he served for two years prior to the company’s acquisition by bristolmyers squibb company in  while at medarex mr pien shepherded the evolution of the company from a technology platform enterprise to a promising developer of oncology and immunology product candidates prior to medarex he served as president and chief executive officer of chiron corporation from  until its acquisition by novartis in  mr pien held an year tenure at glaxosmithkline and its predecessor smithkline beecham most recently serving as president of glaxosmithkline international earlier in his career mr pien held roles of increasing responsibility at abbott laboratories and at merck  co “sage’s targeted and differentiated approach to drug identification is compelling and has shown promise in developing treatments for critical and orphan cns diseases” said mr pien “i am privileged to join the very talented sage team as the company works to discover develop and deliver important new medicines to patients in need” about sage therapeutics sage therapeutics is a neurosciencefocused company developing medicines to treat lifethreatening rare cns disorders sage’s lead program sage is in clinical development for superrefractory status epilepticus srse and is the first of many compounds the company is developing in its portfolio of potential seizure medicines sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors which have demonstrated preclinical activity sage therapeutics is a private company launched in  by an experienced team of rd leaders cns experts and investors for more information please visit wwwsagerxcom contacts pure communicationsdan budwick danpurecommunicationsinccom release summary sage therapeutics appoints howard h pien to the company’s board of directors contacts pure communicationsdan budwick danpurecommunicationsinccom search advanced news search advanced news search log in sign up howard pien  glaxosmithkline plc  zoominfocom howard h pien  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in howard h pien board member at immunogen inc view full profile are you howard h pien claim your profile   sign up for equilar atlas and view howard h piens full profile with equilar atlas you can identify corporate executives in howard h piens network and community follow changes in howard h piens employment and moneyinmotion connect with howard h pien through your network of contacts howard h piens executive work history current board member juno therapeutics inc board member immunogen inc past to view howard h piens complete executive work history sign up now education bs massachusetts institute of technology mba carnegie mellon university age      howard h piens biography howard pien mr pien has served as a member of our board of directors since march  mr pien was the chairman of the board and chief executive officer of medarex inc from  to its acquisition by bristolmyers squibb company in  prior to that he was a private consultant from  to  prior to  he was president and chief executive officer of chiron corporation from  to its acquisition by novartis in  and before that mr pien held positions of increasing responsibility at glaxosmithkline and its predecessor smithkline beecham at abbott laboratories and at merck  co mr pien currently serves on the board of  read more howard pien mr pien has served as a member of our board of directors since march  mr pien was the chairman of the board and chief executive officer of medarex inc from  to its acquisition by bristolmyers squibb company in  prior to that he was a private consultant from  to  prior to  he was president and chief executive officer of chiron corporation from  to its acquisition by novartis in  and before that mr pien held positions of increasing responsibility at glaxosmithkline and its predecessor smithkline beecham at abbott laboratories and at merck  co mr pien currently serves on the board of directors of indivior plc as nonexecutive chairman juno therapeutics inc as chairman and immunogen inc and vanda pharmaceuticals inc as chairman from  to  previously mr pien served on the board of directors of viropharma incorporated as lead independent director ikaria holdings inc pharmaceutical research and manufacturers of america phrma biotechnology innovation organization bio and as an advisor to the life sciences practice of warburg pincus a private equity firm mr pien received his mba in finance from carnegie mellon university and his bs in civil engineering from massachusetts institute of technology we believe mr piens qualifications to sit on our board of directors include his extensive experience working for various pharmaceutical and biotechnology companies mr pien has informed us that he will retire from the board of directors immediately prior to the annual meeting and we expect that he will continue to serve on the board of directors until such time source sage therapeutics inc on    sign up for equilar atlas and view howard h piens full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like howard h pien more specifically youll be able to identify corporate executives in howard h piens network and community follow changes in howard h piens employment and moneyinmotion connect with howard h pien through your network of conections view full profile   search for over  executive profiles bio example howard h pien howard h piens connections  sign up now to view howard h piens  connections » steven m paul dir president and chief executive officer voyager therapeutics inc kevin p starr board member alnylam pharmaceuticals inc mark j enyedy dir president and chief executive officer immunogen inc marc tessierlavigne scientific advisor agios pharmaceuticals inc jack goldstein board member accuray incorporated raymund breu former chief financial officer novartis ag robert w azelby executive vice president and chief commercial officer juno therapeutics inc james j oleary former vice president and chief medical officer immunogen inc thomas o daniel board member zafgen inc gian p reverberi senior vice president chief commercial officer and general manager europe vanda pharmaceuticals inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla daniel a dematteo executive chairman gamestop corp david j oconnor president and ceo the madison square garden company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   imgn howard h pien insider trades for immunogen inc bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close immunogen inc nasdaq imgn go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus immunogen inc after hours  quotes are delayed by  min jul    pm imgn quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual howard h pien mr howard h pien is chairman at indivior plc independent director at sage therapeutics inc nonexecutive chairman at juno therapeutics inc independent director at vanda pharmaceuticals inc independent director at immunogen inc lead independent director at shire viropharma inc and chairman at reckitt benckiser pharmaceuticals inc he is on the board of directors at sage therapeutics inc vanda pharmaceuticals inc immunogen inc shire viropharma inc biotechnology industry organization and pharmaceutical research  manufacturers of america mr pien was previously employed as lead independent director by ikaria inc chairman president  chief executive officer by medarex inc president chief executive officer  director by chiron corp presidentpharmaceuticals international by glaxosmithkline plc presidentpharmaceuticals operations by smithkline beecham plc a principal by abbott laboratories and vice president by merck  co inc he also served on the board at talon therapeutics inc arresto biosciences inc viropharma inc bellerophon therapeutics inc and ucsf benioff childrens hospital oakland he received his undergraduate degree from the massachusetts institute of technology and an mba from carnegie mellon university transactions date shares transaction value copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr mark j enyedy president chief executive officer  director mr david b johnston chief financial officer  executive vice president dr thomas ryll vice presidenttechnical operations dr anna berkenblit chief medical officer  vice president dr richard j gregory chief scientific officer  executive vp mr peter j williams vice presidentbusiness development dr john m lambert executive vice president mr daniel m junius director ms sarah kiely investor relation contact ms ellie harrison chief human resources officer  vice president mr craig barrows secretary vice president  general counsel dr theresa g wingrove vice presidentregulatory affairs mr stephen c mccluski chairman mr howard h pien independent director mr dean jonathan mitchell independent director ms kristine peterson independent director dr mark alan goldberg independent director mr richard j wallace independent director dr joseph j villafranca independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pat least  dead after overheated tractortrailer found outside texas walmart p‘full transparency’ doesn’t mean what scaramucci apparently thinks it means pstocks brace for volatility in earnings deluge fed meeting looms pthe dark side of cruises pif you suddenly quit your job like sean spicer here’s what you should do next pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pnever ever say these things to a coworker pmy uncle with dementia needs longterm care — should i refinance his house pthis is the deadliest time of your life to put on weight p easily avoidable reasons why millennials can’t have nice things or save any money pwhy house prices in gay neighborhoods are soaring pnearly  of adults don’t have life insurance — these startups are trying to change that pmarie kondo says this one thing could be holding you back from falling in love pthis luxury credit card is only for truly big spenders phow elon musk and shorter commutes could transform people’s lives pbanks have raised creditcard interest rates — but not savings account rates pthe most expensive city in the world is not new york or san francisco p in  americans say they will die in debt pshopping at costco and  other things that prove rich people are cheap aheavy showers swamp new orleans street with rainwater loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  form  juno therapeutics inc for jul  filed by pien howard h research stocks news story skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  news  events  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print format change text size default text sizea larger text sizea largest text sizea form  juno therapeutics inc for jul  filed by pien howard h by k wizard—  pm et  httparchivefastedgarcomarzcztibzzhkezrz filed on july   more juno news daily technical summary reports on biotech stocks  juno therapeutics lexicon pharma nantkwest and nektar therapeutics pr newswire   am et  biotech stocks showing signs of resurgence pr newswire   am et  juno therapeutics presents transcend nhl  trial data at international conference on malignant lymphoma business wire   am et  copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top bofi log in for events hafc an earn epam sn log in for events chkp lho fit gts find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  pm et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  juno stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsjuno juno therapeutics inc    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all tcell cancer therapy holds promise longerterm results await reuters –  am et  a novel cell treatment that saved the life of yearold austin schuetz was given the green light by us regulatory advisers on wednesday and doctors hope it can save the lives of more children with the most common type of childhood cancer us fda panel backs novartis pioneering new cancer gene therapy reuters –  pm et  novartis ags pioneering new cancer drug won enthusiastic support from a federal advisory panel on wednesday paving the way for approval of the first us gene therapy the panel unanimously recommended that the food and drug administration approve the drug tisagenlecleucel for patients ages  to  with relapsed bcell acute lymphoblastic leukemia the most common form of us childhood cancer pioneering cancer gene therapy by novartis backed by us panel reuters –  pm et  novartis ags pioneering cancer drug won the backing of a federal advisory panel on wednesday paving the way for the first gene therapy to be approved in the united states novartis readies for fda review of  bln cart child cancer hope reuters –  am et   fda to review novartiss ctl on wednesday  novartis poised to beat kite juno in cart race  key drug component inventors long unacknowledged by john miller two decades ago in a memphis tenn hospital lab cancer scientist dario campana and his team were hunting for a new way to fight deadly acute lymphoblastic leukemia daily technical summary reports on biotech stocks  juno therapeutics lexicon pharma nantkwest and nektar therapeutics pr newswire –  am et  new york july   if you want a stock review on juno lxrx nk or nktr then come over to httpdailystocktrackercomregister and sign up for your free customized report today httpdailystocktrackercomregister juno therapeutics  on thursday shares in seattle washington headquartered juno therapeutics inc juno recorded a trading volume of  million shares biotech stocks showing signs of resurgence pr newswire –  am et  palm beach florida june   the nasdaq biotechnology index surged last week as research and development for the advancement of rare cancer therapies and anticancer drug candidates heat up with new partnerships with mayo clinic as part of a process for creating and delivering treatments to reach the patients who need them the most juno therapeutics presents transcend nhl  trial data at international conference on malignant lymphoma business wire –  am et    overall response and  complete response at three months in core group moving to pivotal trial of those patients in response at three months  continue in response at six months   of patients experienced no cytokine release syndrome or neurotoxicity in core group moving into pivotal trial   of core group patients experienced severe neurotoxicity and  experienced severe cyt briefjuno therapeutics says court decides it lacks jurisdiction over kite pharma lawsuit reuters –  am et  juno therapeutics inc juno  court decides it lacks jurisdiction before fda approval occurs  juno therapeutics juno  us district court for district of delaware decided it lacked jurisdiction at this time over a lawsuit filed against kite pharma court decides it lacks jurisdiction before fda approval occurs business wire –  am et  juno therapeutics inc juno a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer announced today that the us district court for the district of delaware decided it lacked jurisdiction at this time over a lawsuit filed against kite pharma inc citing the absence of evidence that an fda approval decision of kites lead product candidate axicabta juno therapeutics stock drops  after btig downgrades to sell marketwatch –  am et  juno therapeutics inc juno shares dropped  in premarket trade thursday after btig downgraded it to sell from neutral with a  price target juno shares closed at  on wednesday the company is trailing competitors like kite pharma inc kite and novartis ag nvs to market and there is little demonstrative proof that juno drugs work better or have fewer lifethreatening side effects btig analyst dane leone said juno therapeutics stock drops  after btig downgrades to sell marketwatch –  am et  novartis touts new tcell therapy data in race for fda approval reuters –  am et  novartis on wednesday touted new data from its tcell therapy ctl saying it is on a par with results of experimental molecules from kite pharma kite and juno therapeutics juno that also target aggressive blood cancers blood and bone marrow therapies grab spotlight at worlds top cancer meeting reuters –  am et  promising new data on blood and bone marrow cancer therapies that reengineer immune system cells are convincing more doctors of the validity of the approach according to reuters interviews at the worlds biggest annual oncology meeting juno therapeutics to present at the goldman sachs th annual global healthcare conference business wire –  pm et  juno therapeutics inc juno today announced that it will webcast its presentation at the goldman sachs th annual global healthcare conference at  am pt on tuesday june   kite to launch midstage leukemia trial in fourth quarter  reuters –  am et  kite pharma inc kite said on monday it planned to launch in the fourth quarter of this year a phase  trial of its experimental tcell therapy in leukemia patients possibly at a lower dose than is currently being tested juno therapeutics presents updated transcend nhl  trial data demonstrating high durable response rates in patients with relapsed or refractory cd aggressive nonhodgkin lymphoma business wire –  am et   first multicenter car t trial to treat a wide range of patients with aggressive relapsed or refractory nhl excluded from other trials   overall response rate and  complete response at three months in core analysis group moving into pivotal trial  of those patients with a response at three months continuing in response at six months   of patients experienced severe neurotoxicity biotech stocks under scanner  juno therapeutics nektar therapeutics threshold pharma and bellerophon therapeutics pr newswire –  am et  new york may   the biotech space consists of companies engaged in the research and development of new drugs medical devices and procedures httpstockcallerscomregistration juno therapeutics juno   shares in seattle washington headquartered juno therapeutics inc juno rose  ending wednesdays trading session at  the stock recorded a trading volume of  shares juno therapeutics appoints jay flatley to board of directors business wire –  am et  juno therapeutics juno inc a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer today announced it has appointed jay flatley to its board of directors a successful entrepreneur mr flatley brings to junos board his considerable experience building a highly successful and innovative healthcare company juno therapeutics to present key clinical data updates on jcar and jcar at the  american society of clinical oncology annual meeting business wire –  pm et  juno therapeutics inc juno a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer today announced that it will present key clinical updates in partnership with its collaborators on its investigational products jcar and jcar at the upcoming american society of clinical oncology annual meeting  in chicago illinois june  juno therapeutics to present at the bank of america merrill lynch  health care conference business wire –  pm et  juno therapeutics inc juno today announced that it will webcast its presentation at the bank of america merrill lynch  health care conference at  pm pt on tuesday may   page page   next  todays and upcoming events aug  juno to announce q earnings after market unconfirmed past events last  days jun  shareholders meeting data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe immunogen  about us  board of directors twitter go about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governanceexecutive officersboard of directorscommittee compositionfinancials  filingsstock informationcontact uscareersbenefits about usmissionexecutive officersboard of directorsin the communitycontact usour adc technologywhat is an adcadc designwith checkpoint inhibitorsour partnerskadcylapipelinemirvetuximab soravtansineimgnimgncoltuximab ravtansineclinical trialspartner compoundspublicationsinvestorspress releasesevents  presentationscorporate governancefinancials  filingsstock informationcontact uscareersbenefits go board of directors stephen c mccluski  chairman of the board stephen c mccluski has been a director of immunogen since  and has served as the chairman of our board of directors since  mr mccluski served as senior vice president and chief financial officer of bausch  lomb incorporated from  to his retirement in  mr mccluski is also a director of monro muffler brake inc and the james p wilmot cancer center of the university of rochester mark enyedy  president and chief executive officer mr enyedy joined immunogen in  as president and ceo bringing over twentyfive years of combined general management business development and legal experience in the biotechnology industry he joined immunogen from shire plc where he served as executive vice president and head of corporate development leading the companys strategy ma and corporate planning functions and providing commercial oversight for the companys prephase  portfolio previously mr enyedy served as ceo of proteostasis therapeutics inc following  years at genzyme corporation in diverse roles most recently as president of the transplant oncology and multiple sclerosis divisions before joining genzyme mr enyedy was an associate with the boston law firm palmer  dodge he holds a jd from harvard law school and a bs from northeastern university mr enyedy also serves on the board of directors of fate therapeutics mark goldberg md mark goldberg md has been a director of immunogen since  dr goldberg served in various capacities of increasing responsibility at synageva biopharma corp a biopharmaceutical company from  to  including as executive vice president medical and regulatory strategy of product development from october  through the aquisition of synageva by alexion pharmaceuticals inc in june  dr goldberg while no longer an officer remained employed by synageva contributing to medical and regulatory strategy prior to joining synageva he served in various management capacities of increasing responsibility at genzyme corporation from  to  most recently as senior vice president clinical research and global therapeutic head oncology genetic health and as chairman of genzyme’s early product review board prior to joining genzyme he was a fulltime staff physician at brigham and women’s hospital and the danafarber cancer institute where he still holds appointments dr goldberg is an associate professor of medicine at harvard medical school dr goldberg holds a doctor of medicine degree from harvard medical school dr goldberg is also a director of atyr pharma inc blueprint medicines corporation glycomimetics inc and idera pharmaceuticals inc daniel m junius daniel m junius has been a director of immunogen since  mr junius joined immunogen in  and served as our president and chief executive officer from  mr junius holds a master of management from northwestern university’s kellogg school of management mr junius is also a director of idexx laboratories inc and glycomimetics inc dean mitchell dean j mitchell has been a director of immunogen since  mr mitchell has served as executive chairman of the board of covis pharma holdings sarl since  prior to that he served as president and chief executive officer of lux biosciences inc from  to august  prior to that he served as president and chief executive officer of alpharma inc from  until its acquisition by king pharmaceuticals inc in  prior to that he served as president and chief executive officer of guilford pharmaceuticals inc from  until its acquisition by mgi pharma inc in  prior to that he served in various senior executive capacities in the worldwide medicines group of bristolmyers squibb company from  to  prior to that he spent  years at glaxosmithkline plc in assignments of increasing responsibility spanning sales marketing general management commercial strategy and clinical development and product strategy mr mitchell is also a director of inrexon inc and theravance biopharma inc kristine peterson kristine peterson has served as director of immunogen since  ms peterson served as chief executive officer of valeritas inc from  prior to that she served as company group chair of johnson  johnson’s biotech groups from  to  and as executive vice president for jj’s global strategic marketing organization from  to  prior to that she served as senior vice president commercial operations for biovail corporation and president of biovail pharmaceuticals from  to  prior to that she spent  years at bristolmyers squibb company in assignments of increasing responsibility spanning marketing sales and general management including running a cardiovascularmetabolic business unit and a generics division ms peterson is also a director of amarin corporation plc and paratek pharmaceuticals inc howard h pien howard h pien has served as a director of immunogen since  mr pien has most recently served as chairman of the board and chief executive officer of medarex inc from  to its acquisition by bristolmyers squibb company in  prior to that he was a private consultant from  to  prior to that he served as president and chief executive officer of chiron corporation from  to its acquisition by novartis ag in  prior to that he served in various executive capacities at glaxosmithkline plc gsk and its predecessor companies including as president of gsk’s international pharmaceuticals business from  to  and as president of pharmaceutical operations of smithkline beecham plc a predecessor of gsk mr pien also worked for six years at abbott laboratories and for five years at merck  co inc in positions in sales market research licensing and product management mr pien is also currently an advisor to the life sciences practice of warburg pincus a private equity firm as well as a director of indivior plc as nonexecutive chairman juno therapeutics inc as nonexecutive chairman and sage therapeutics inc joseph j villafranca phd joseph j villafranca phd has served as director of immunogen since  dr villafranca has served as president of biopharmaceutical consultants llc since  prior to that he served as senior vice president sou head life sciences of tunnell consulting from  to his retirement from tunnell consulting in  prior to that he served as senior vice president – operations and principal  practice director life sciences of tunnell consulting from  to  prior to that he served as president of biopharmaceutical consultants llc from  to  prior to that he served as executive vice president pharmaceutical development and operations at neose technologies inc from  to  prior to that he served in various executive positions at bristolmyers squibb company over a period of  years dr villafranca holds a phd in biochemistrychemistry from purdue university and completed his postdoctoral work at the institute for cancer research in philadelphia pennsylvania richard j wallace richard j wallace has been a director of immunogen since  mr wallace served as a senior vice president for research and development at glaxosmithkline plc gsk from  to his retirement in  prior to that he served in various executive capacities for gsk and its predecessor companies and their subsidiaries from  to  mr wallace’s experience prior to joining gsk included eight years with bristolmyers squibb company and seven years at johnson  johnson in assignments spanning marketing sales manufacturing and general management mr wallace is also a director of gnc holdings inc last updated december  about usmissionexecutive officersboard of directorsin the communitycontact us   immunogen inc sitemap  privacy policy  usage policy you are now leaving this website if you would like to continue click continue cancelcontinue